Dong-A ST Co., Ltd. (170900.KS)
KRW 47300.0
(-1.77%)
KRW 47300.0
(-1.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 306.95 Billion KRW | 4.3% |
| 2022 | 298.21 Billion KRW | 7.17% |
| 2021 | 278.25 Billion KRW | 11.15% |
| 2020 | 250.34 Billion KRW | -1.99% |
| 2019 | 255.42 Billion KRW | 0.62% |
| 2018 | 253.86 Billion KRW | -0.87% |
| 2017 | 256.08 Billion KRW | -2.23% |
| 2016 | 261.92 Billion KRW | 6.24% |
| 2015 | 246.53 Billion KRW | -5.45% |
| 2014 | 260.75 Billion KRW | 15.83% |
| 2013 | 225.13 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 92.89 Billion KRW | -0.31% |
| 2024 Q2 | 90.38 Billion KRW | -2.71% |
| 2023 Q2 | -77.72 Billion KRW | -207.27% |
| 2023 Q3 | -71.87 Billion KRW | 7.52% |
| 2023 Q1 | 72.46 Billion KRW | -16.23% |
| 2023 Q4 | 93.18 Billion KRW | 229.64% |
| 2023 FY | 311.03 Billion KRW | 4.3% |
| 2022 Q4 | 86.5 Billion KRW | 27.43% |
| 2022 Q2 | 76.26 Billion KRW | 212.88% |
| 2022 Q1 | -67.56 Billion KRW | -187.1% |
| 2022 FY | 298.21 Billion KRW | 7.17% |
| 2022 Q3 | 67.88 Billion KRW | -11.0% |
| 2021 Q1 | 69.13 Billion KRW | -7.1% |
| 2021 Q3 | 66.26 Billion KRW | 1.49% |
| 2021 Q4 | 77.57 Billion KRW | 17.06% |
| 2021 FY | 278.25 Billion KRW | 11.15% |
| 2021 Q2 | 65.29 Billion KRW | -5.56% |
| 2020 Q3 | 60 Billion KRW | 2.83% |
| 2020 FY | 250.34 Billion KRW | -1.99% |
| 2020 Q2 | 58.35 Billion KRW | 1.35% |
| 2020 Q1 | 57.57 Billion KRW | -16.85% |
| 2020 Q4 | 74.41 Billion KRW | 24.02% |
| 2019 FY | 255.42 Billion KRW | 0.62% |
| 2019 Q4 | 69.24 Billion KRW | 14.51% |
| 2019 Q3 | 60.46 Billion KRW | -6.9% |
| 2019 Q2 | 64.94 Billion KRW | 6.87% |
| 2019 Q1 | 60.77 Billion KRW | -10.12% |
| 2018 Q2 | 65.09 Billion KRW | 7.03% |
| 2018 FY | 253.86 Billion KRW | -0.87% |
| 2018 Q3 | 60.33 Billion KRW | -7.31% |
| 2018 Q4 | 67.61 Billion KRW | 12.07% |
| 2018 Q1 | 60.81 Billion KRW | -16.96% |
| 2017 Q2 | 63.61 Billion KRW | 4.52% |
| 2017 Q1 | 60.86 Billion KRW | -7.17% |
| 2017 Q3 | 58.36 Billion KRW | -8.25% |
| 2017 FY | 256.08 Billion KRW | -2.23% |
| 2017 Q4 | 73.24 Billion KRW | 25.49% |
| 2016 Q4 | 65.56 Billion KRW | 5.91% |
| 2016 FY | 261.92 Billion KRW | 6.24% |
| 2016 Q1 | 65.41 Billion KRW | -1.07% |
| 2016 Q2 | 72.42 Billion KRW | 10.71% |
| 2016 Q3 | 61.9 Billion KRW | -14.52% |
| 2015 FY | 246.53 Billion KRW | -5.45% |
| 2015 Q3 | 61.54 Billion KRW | 1.09% |
| 2015 Q2 | 60.88 Billion KRW | 5.01% |
| 2015 Q1 | 57.97 Billion KRW | -10.07% |
| 2015 Q4 | 66.12 Billion KRW | 7.44% |
| 2014 Q1 | 68.86 Billion KRW | -0.67% |
| 2014 Q2 | 68.89 Billion KRW | 0.04% |
| 2014 Q3 | 58.52 Billion KRW | -15.06% |
| 2014 Q4 | 64.47 Billion KRW | 10.17% |
| 2014 FY | 260.75 Billion KRW | 15.83% |
| 2013 Q2 | 66.8 Billion KRW | 194.76% |
| 2013 FY | 225.13 Billion KRW | 0.0% |
| 2013 Q1 | 22.66 Billion KRW | 0.0% |
| 2013 Q3 | 66.26 Billion KRW | -0.81% |
| 2013 Q4 | 69.33 Billion KRW | 4.63% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -549.592% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | -3.009% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -76.262% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -17.628% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | -10.242% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -167.56% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -343.493% |
| Yuhan Corporation | 489.94 Billion KRW | 37.349% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -634.533% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -326.429% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -666.376% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -228.116% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -142.86% |
| CKD Bio Corp. | 25.19 Billion KRW | -1118.291% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -549.592% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -309.009% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -423.423% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -28.482% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -140.432% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -349.353% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -341.866% |
| HANDOK Inc. | 153.76 Billion KRW | -99.623% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -549.592% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -23.216% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 45.228% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -28.482% |
| Yuhan Corporation | 489.94 Billion KRW | 37.349% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -58.5% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 49.759% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 24.886% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -447.825% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -28.482% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 12.477% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -622.734% |
| JW Holdings Corporation | 301.25 Billion KRW | -1.892% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -366.846% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -75.478% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -140.432% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -38.27% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -159.663% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -362.165% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -85.907% |
| Boryung Corporation | 285.16 Billion KRW | -7.643% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -250.64% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -76.262% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1414.974% |